Hikma Pharmaceuticals Plc (LON:HIK) had its target price reduced by JPMorgan Chase & Co. from GBX 2,550 ($33.29) to GBX 2,450 ($31.98) in a research report released on Wednesday. JPMorgan Chase & Co. currently has an overweight rating on the stock.

Several other equities analysts have also recently commented on HIK. Stifel Nicolaus reiterated a buy rating on shares of Hikma Pharmaceuticals Plc in a research note on Friday, June 24th. Jefferies Group increased their target price on Hikma Pharmaceuticals Plc from GBX 2,380 ($31.07) to GBX 2,800 ($36.55) and gave the company a buy rating in a research note on Tuesday, July 5th. Morgan Stanley initiated coverage on Hikma Pharmaceuticals Plc in a research note on Thursday, July 21st. They set an equal weight rating and a GBX 2,700 ($35.24) target price for the company. Numis Securities Ltd initiated coverage on Hikma Pharmaceuticals Plc in a research note on Friday, July 22nd. They set an add rating and a GBX 2,830 ($36.94) target price for the company. Finally, Barclays PLC reiterated an overweight rating and set a GBX 2,800 ($36.55) target price on shares of Hikma Pharmaceuticals Plc in a research note on Thursday, August 4th. Three research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company’s stock. The stock has a consensus rating of Buy and an average target price of GBX 2,520.90 ($32.91).

Hikma Pharmaceuticals Plc (LON:HIK) opened at 2152.00 on Wednesday. Hikma Pharmaceuticals Plc has a 52-week low of GBX 1,575.00 and a 52-week high of GBX 2,703.00. The company has a 50-day moving average of GBX 2,252.71 and a 200-day moving average of GBX 2,229.68. The stock’s market capitalization is GBX 4.86 billion.

In related news, insider Darwazah,Said purchased 200,000 shares of the firm’s stock in a transaction that occurred on Friday, August 26th. The stock was acquired at an average price of GBX 2,160 ($28.19) per share, for a total transaction of £4,320,000 ($5,638,950.53). Also, insider Al-Husry,Ali purchased 50,000 shares of the firm’s stock in a transaction that occurred on Friday, September 16th. The stock was bought at an average price of GBX 2,119 ($27.66) per share, with a total value of £1,059,500 ($1,382,978.72).

Hikma Pharmaceuticals Plc Company Profile

Hikma Pharmaceuticals Plc is a pharmaceutical company. The Company develops, manufactures and markets a range of branded and non-branded generic pharmaceutical products in solid, semi-solid, liquid and injectable final dosage forms, across the United States, the Middle East and North Africa (MENA) region and Europe.

Receive News & Ratings for Hikma Pharmaceuticals Plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hikma Pharmaceuticals Plc and related companies with Analyst Ratings Network's FREE daily email newsletter.